[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0923786A2 - compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos - Google Patents

compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos

Info

Publication number
BRPI0923786A2
BRPI0923786A2 BRPI0923786A BRPI0923786A BRPI0923786A2 BR PI0923786 A2 BRPI0923786 A2 BR PI0923786A2 BR PI0923786 A BRPI0923786 A BR PI0923786A BR PI0923786 A BRPI0923786 A BR PI0923786A BR PI0923786 A2 BRPI0923786 A2 BR PI0923786A2
Authority
BR
Brazil
Prior art keywords
phenylbenzo
isoquinoline
dihydro
substituted
amine compounds
Prior art date
Application number
BRPI0923786A
Other languages
English (en)
Inventor
David Vensel
Eugene Kelleher
Hui Wu
Jean-Marc Lapierre
Manish Tandon
Mark Ashwell
Neil Westlund
Nivedita Namdev
Rocio Palma
Rui-Yang Yang
Sudharshan Eathiraj
Syed M Ali
Yanbin Liu
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of BRPI0923786A2 publication Critical patent/BRPI0923786A2/pt
Publication of BRPI0923786B1 publication Critical patent/BRPI0923786B1/pt
Publication of BRPI0923786C1 publication Critical patent/BRPI0923786C1/pt
Publication of BRPI0923786C8 publication Critical patent/BRPI0923786C8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/541,3-Diazines; Hydrogenated 1,3-diazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/10Aza-phenanthrenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0923786A 2008-12-30 2009-12-30 compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos BRPI0923786C8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14143908P 2008-12-30 2008-12-30
US61/141.439 2008-12-30
US26050509P 2009-11-12 2009-11-12
US61/260.505 2009-11-12
PCT/US2009/069813 WO2010078421A1 (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds

Publications (4)

Publication Number Publication Date
BRPI0923786A2 true BRPI0923786A2 (pt) 2016-07-26
BRPI0923786B1 BRPI0923786B1 (pt) 2020-11-24
BRPI0923786C1 BRPI0923786C1 (pt) 2021-05-11
BRPI0923786C8 BRPI0923786C8 (pt) 2021-05-25

Family

ID=41682678

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923786A BRPI0923786C8 (pt) 2008-12-30 2009-12-30 compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos

Country Status (14)

Country Link
US (1) US8357694B2 (pt)
EP (1) EP2379506B1 (pt)
JP (1) JP5739820B2 (pt)
KR (1) KR101714799B1 (pt)
CN (1) CN102325755B (pt)
BR (1) BRPI0923786C8 (pt)
CA (1) CA2748491C (pt)
DK (1) DK2379506T3 (pt)
ES (1) ES2554623T3 (pt)
IL (1) IL213787A (pt)
MX (1) MX2011006959A (pt)
TW (1) TWI461410B (pt)
WO (1) WO2010078421A1 (pt)
ZA (1) ZA201104706B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
MX2014000621A (es) 2011-07-15 2014-11-10 Abbvie Inc Inhibidores triciclicos de cinasas utiles para el tratamiento de enfermedades proliferativas.
GB2499666A (en) * 2012-02-27 2013-08-28 Nanyang Polytechnic Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
AU2015304465B2 (en) 2014-08-18 2019-05-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
MX2017002892A (es) * 2014-09-05 2017-06-06 Arqule Inc Composiciones y metodos para tratar trastornos de proliferacion.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
KR20180085814A (ko) 2015-12-17 2018-07-27 아르퀼 인코포레이티드 치환된 5,6-디히드로-6-페닐벤조[f]이소퀴놀린-2-아민의 제조 방법
TWI796250B (zh) * 2015-12-17 2023-03-11 美商亞闊股份有限公司 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3788046A1 (en) 2018-05-04 2021-03-10 Incyte Corporation Salts of an fgfr inhibitor
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
KR20210066839A (ko) * 2018-09-27 2021-06-07 베타 파머수티컬 컴퍼니 리미티드 Fgfr4 저해제 및 그것의 용도
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Fgfr阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN116601155A (zh) * 2020-11-26 2023-08-15 成都赛璟生物医药科技有限公司 杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN113354630B (zh) * 2021-06-30 2022-11-01 江南大学 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用
AR127448A1 (es) * 2021-10-25 2024-01-24 Basilea Pharmaceutica Int Ag Allschwil Derivados de benzo[h]quinazolin-4-amina para el tratamiento del cáncer
WO2023196629A1 (en) * 2022-04-07 2023-10-12 Redona Therapeutics, Inc. Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2623846A1 (de) 1976-05-28 1977-12-15 Hoechst Ag 4-chinazolinyl-guanidine und verfahren zu ihrer herstellung
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1154024B (it) 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
US4814335A (en) 1982-12-30 1989-03-21 Biomeasure, Incorporated Antiviral compounds
US4625026A (en) 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
DD240010A1 (de) 1985-03-22 1986-10-15 Univ Berlin Humboldt Verfahren zur herstellung von substituierten 2-imino-1h-pyridin-1-aminen
SU1540240A1 (ru) 1988-05-16 1995-09-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 5-ЗАМЕЩЕННЫЕ 1-АМИНО -8,9-ДИГИДРО -8,8-ДИМЕТИЛ-3, 6Н- ПИРАЗОЛО [3,4-B] ПИРАНО[[4′,3′-d]] ПИРИДИНА ИЛИ ИХ ГИДРОХЛОРИДЫ, ОБЛАДАЮЩИЕ ПРОТИВОСУДОРОЖНОЙ АКТИВНОСТЬЮ
DD280109A1 (de) 1989-02-22 1990-06-27 Univ Berlin Humboldt Verfahren zur herstellung substituierter 1.2.4-triazolo/1.5-a/-pyridine
SU1626648A1 (ru) 1989-07-20 1995-09-27 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 1-амино-8,9- дигидро-5,8,8- триметил-3,6н- пиразоло[3,4-b] тиопирано [4,3-d]пиридин или его гидрохлорид, обладающие противосудорожной активностью
DE4117802A1 (de) 1991-05-30 1992-12-03 Berlin Chemie Ag 2-aminopyridin-3-carbonitrile als selektive hemmstoffe des humanen cytomegalievirus
WO1995008539A1 (en) 1993-09-24 1995-03-30 The Du Pont Merck Pharmaceutical Company Improved methods for preparing bis-imide compounds
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
CN1118460C (zh) * 1995-10-02 2003-08-20 弗·哈夫曼-拉罗切有限公司 作为5HTzc-受体拮抗剂的嘧啶衍生物
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
CN1242993C (zh) 2000-03-31 2006-02-22 日本新药株式会社 杂环衍生物和药物
US20040116450A1 (en) 2001-03-19 2004-06-17 Tatsuya Oyama Antipruritics
US7077898B2 (en) 2003-07-17 2006-07-18 Ciba Specialty Chemicals Corporation Black pigment compositions
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2546894C (en) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
EP1773840B1 (de) 2004-07-23 2010-01-20 The Medicines Company (Leipzig) GmbH Substituierte pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
ES2354267T3 (es) 2005-02-09 2011-03-11 Arqule, Inc. Derivados de maleimida, composiciones farmacéuticas y métodos para el tratamiento del cáncer.
WO2007023243A2 (en) 2005-08-24 2007-03-01 Protherics Medicines Development Limited Cleavage of antifolate compounds
TW200811173A (en) 2006-02-15 2008-03-01 Abbott Lab Pyrazoloquinolones are potent PART inhibitors
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
CN104860930A (zh) 2006-12-29 2015-08-26 里格尔制药公司 用作axl抑制剂的取代三唑

Also Published As

Publication number Publication date
WO2010078421A1 (en) 2010-07-08
KR101714799B1 (ko) 2017-03-09
CN102325755B (zh) 2015-07-01
BRPI0923786C8 (pt) 2021-05-25
ES2554623T3 (es) 2015-12-22
DK2379506T3 (en) 2015-12-14
AU2009335010A8 (en) 2011-08-11
AU2009335010A1 (en) 2011-07-21
IL213787A0 (en) 2011-07-31
TWI461410B (zh) 2014-11-21
EP2379506B1 (en) 2015-09-02
EP2379506A1 (en) 2011-10-26
BRPI0923786B1 (pt) 2020-11-24
CA2748491C (en) 2019-08-06
CN102325755A (zh) 2012-01-18
BRPI0923786C1 (pt) 2021-05-11
WO2010078421A8 (en) 2011-10-27
MX2011006959A (es) 2011-12-06
KR20110099790A (ko) 2011-09-08
ZA201104706B (en) 2012-08-29
TW201035055A (en) 2010-10-01
JP2012514045A (ja) 2012-06-21
US8357694B2 (en) 2013-01-22
CA2748491A1 (en) 2010-07-08
US20100239525A1 (en) 2010-09-23
IL213787A (en) 2014-08-31
JP5739820B2 (ja) 2015-06-24

Similar Documents

Publication Publication Date Title
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0815717A2 (pt) Compostos de imidazopirazina.
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
NO2021006I1 (no) Quofenix, delafloksacin
BRPI0813500A2 (pt) Compostos antivirais
BRPI0821086A2 (pt) Compostos inseticidas
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
BRPI0922904A2 (pt) "compostos"
BRPI0918472A2 (pt) composto 2,4-diaminopirimidina
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0920707A2 (pt) compostos
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
BRPI0908353A2 (pt) Compostos
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
CR10353A (es) Nuevos compuestos.
BRPI0811264A2 (pt) Compostos
BRPI0918602A2 (pt) composto (i)
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0809996A2 (pt) Compostos
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2603 DE 24/11/2020 QUANTO AO ENDERECO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF